TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions by Daver, NG, Maiti, A, Kadia, TM, Vyas, P, Majeti, R, Wei, AH, Garcia-Manero, G, Craddock, C, Sallman, DA, Kantarjian, HM

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, p... by DiNardo, CD, Schuh, AC, Stein, EM, Montesinos, P, Wei, AH, de Botton, S, Zeidan, AM, Fathi, AT, Kantarjian, HM, Bennett, JM, Frattini, MG, Martin-Regueira, P, Lersch, F, Gong, J, Hasan, M, Vyas, P, Döhner, H

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, GD, Smith, S, Garcia, JS, Bose, P, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Stoilova, B, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, CA, Garcia, JS, Borthakur, G, Loghavi, S, Zeng, Z, Tippett, GD, Kadia, TM, Masarova, L, Yilmaz, M, Maiti, A, Bose, P, Takahashi, K, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, G, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Sweet, K, Kantarjian, HM, Garcia-Manero, G, Komrokji, R, Xing, G, Ramsingh, G, Renard, C, Zeidner, JF, Sallman, DA

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib by Stein, EM, Dinardo, CD, Fathi, AT, Pollyea, DA, Stone, RM, Altman, JK, Roboz, GJ, Patel, MR, Collins, R, Flinn, IW, Sekeres, MA, Stein, AS, Kantarjian, HM, Levine, RL, Vyas, P, Macbeth, KJ, Tosolini, A, Vanoostendorp, J, Xu, Q, Gupta, I, Lila, T, Risueno, A, Yen, KE, Wu, B, Attar, EC, Tallman, MS, De Botton, S

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia by DiNardo, CD, Stein, AS, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Döhner, H, Martinelli, G, Patel, PA, Raffoux, E, Tan, P, Zeidan, AM, de Botton, S, Kantarjian, HM, Stone, RM, Frattini, MG, Lersch, F, Gong, J, Gianolio, DA, Zhang, V, Franovic, A, Fan, B, Goldwasser, M, Daigle, S, Choe, S, Wu, B, Winkler, T, Vyas, P

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia by Stein, EM, DiNardo, CD, Pollyea, DA, Fathi, AT, Roboz, GJ, Altman, JK, Stone, RM, DeAngelo, DJ, Levine, RL, Flinn, IW, Kantarjian, HM, Collins, R, Patel, MR, Frankel, AE, Stein, A, Sekeres, MA, Swords, RT, Medeiros, BC, Willekens, C, Vyas, P, Tosolini, A, Xu, Q, Knight, RD, Yen, KE, Agresta, S, De Botton, S, Tallman, MS